You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 296 No. 13, October 4, 2006 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Letters
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in JAMA
 Topic Collections
 •Drug Therapy
 •Adverse Effects
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Drug Safety Monitoring

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: The Commentary by Dr Strom1 points out several of the problems with the current drug safety monitoring system and offers several suggestions for improving the system. One recommendation calls for the use of independent and complementary nongovernmental organizations in the process of drug safety.

We believe that certified poison control centers (PCCs) fit this requirement and can significantly enhance postmarketing drug surveillance. Poison control centers are staffed with health care professionals trained to obtain detailed medication-related information and health histories, document calls, perform triage, assist in treating patients who are experiencing adverse drug reactions, follow up on outcomes, and perform surveillance. Acting as a focal point for the reporting of suspected adverse drug reactions would be consistent with the public health and surveillance activities currently performed by PCCs.

Data from individual PCCs are sent to the Toxic Exposure Surveillance System (TESS), a surveillance database coordinated by the . . . [Full Text of this Article]

Bruce Ruck, PharmD
bruck@njpies.org

Steven Marcus, MD; John Kashani, DO; Zdravko Vassilev, MD, MPH
New Jersey Poison Information and Education System
New Jersey Medical School
Newark



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLES

Drug Safety Monitoring—Reply
Brian L. Strom
JAMA. 2006;296(13):1590.
EXTRACT | FULL TEXT  

How the US Drug Safety System Should Be Changed
Brian L. Strom
JAMA. 2006;295(17):2072-2075.
EXTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Evaluation of adverse drug reactions reported to a poison control center between 2000 and 2007
Vassilev et al.
Am J Health Syst Pharm 2009;66:481-487.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2006 American Medical Association. All Rights Reserved.